Novel Isatin Conjugates Endowed with Analgesic and Anti-inflammatory Properties: Design, Synthesis and Biological Evaluation

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2024 Dec 16

PMID 39676545

Authors

LaVauria D Brown

Adel S Girgis

Shruti Patel

Nermin Samir

Mona F Said

Anurag T K Baidya

Rajnish Kumar

Jade Moore

Anshuman Khadanga

Rajeev Sakhuja

Siva S Panda

Affiliations

Soon will be listed here.

Abstract

Aims: This study aimed to develop novel molecular hybrid conjugates integrating isatin, rhodanine, and phthalimide pharmacophores to create effective analgesic and anti-inflammatory agents with improved safety profiles over existing treatments.

Materials & Methods: A series of hybrid conjugates () were synthesized and evaluated through in vitro and in vivo biological assays. The most promising compound, , underwent extensive pharmacological and toxicological evaluations. Molecular docking, molecular dynamics simulations, and 2D-QSAR studies were performed to elucidate the mechanism of action and validate the experimental findings.

Results: Compound exhibited potent analgesic and anti-inflammatory activity, effectively inhibiting COX-2 and pro-inflammatory cytokines (IL-6 and TNF-α). Its superior selectivity index (SI) was 1.11 compared to 0.67 for indomethacin. It demonstrated an ulcer index of 2.9 versus 10.23 for indomethacin, indicating reduced gastrointestinal toxicity. Molecular docking simulations revealed a strong binding affinity with COX-2 (-9.832 kcal/mol), and molecular dynamics confirmed the stability of the COX-2 complex.

Conclusions: Compound emerged as a promising lead candidate for developing safer and more effective anti-inflammatory and analgesic agents. Its robust efficacy, safety profile, and computational validation highlight its potential for further optimization in therapeutic applications.

References

van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark A, Berendsen H . GROMACS: fast, flexible, and free. J Comput Chem. 2005; 26(16):1701-18. DOI: 10.1002/jcc.20291. View

Seliem I, Panda S, Girgis A, Tran Q, Said M, Bekheit M . Development of Isatin-Based Schiff Bases Targeting VEGFR-2 Inhibition: Synthesis, Characterization, Antiproliferative Properties, and QSAR Studies. ChemMedChem. 2022; 17(13):e202200164. DOI: 10.1002/cmdc.202200164. View

Shams S, Mehrad-Majd H . TNFα-308G>A Polymorphism and Susceptibility to Immune Thrombocytopenia Purpura (ITP): Evidence From a Systematic Review and Meta-analysis. Cytokine. 2024; 177:156538. DOI: 10.1016/j.cyto.2024.156538. View

Girgis A, Kalmouch A, Ellithey M . Synthesis of novel vasodilatory active nicotinate esters with amino acid function. Bioorg Med Chem. 2006; 14(24):8488-94. DOI: 10.1016/j.bmc.2006.08.041. View

Bradley J . TNF-mediated inflammatory disease. J Pathol. 2007; 214(2):149-60. DOI: 10.1002/path.2287. View

Curreli F, Ahmed S, Victor S, Drelich A, Panda S, Altieri A . Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. Viruses. 2022; 14(1). PMC: 8780828. DOI: 10.3390/v14010069. View

de Oliveira Cardoso M, Moreira D, Oliveira Filho G, Cavalcanti S, Coelho L, Espindola J . Design, synthesis and structure-activity relationship of phthalimides endowed with dual antiproliferative and immunomodulatory activities. Eur J Med Chem. 2015; 96:491-503. DOI: 10.1016/j.ejmech.2015.04.041. View

Sano H, Noguchi T, Tanatani A, Hashimoto Y, Miyachi H . Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide. Bioorg Med Chem. 2005; 13(9):3079-91. DOI: 10.1016/j.bmc.2005.03.002. View

Banarouei N, Davood A, Shafaroodi H, Saeedi G, Shafiee A . N-arylmethylideneaminophthalimide: Design, Synthesis and Evaluation as Analgesic and Anti-inflammatory Agents. Mini Rev Med Chem. 2018; 19(8):679-687. DOI: 10.2174/1389557518666180424101009. View

10.

Tiwari A, Panda S, Girgis A, Sahu S, George R, Srour A . Microwave assisted synthesis and QSAR study of novel NSAID acetaminophen conjugates with amino acid linkers. Org Biomol Chem. 2014; 12(37):7238-49. DOI: 10.1039/c4ob01281j. View

11.

Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M . Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007; 7(1):35-41. DOI: 10.1016/j.autrev.2007.03.003. View

12.

Cheke R, Patil V, Firke S, Ambhore J, Ansari I, Patel H . Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery. Pharmaceuticals (Basel). 2022; 15(3). PMC: 8950263. DOI: 10.3390/ph15030272. View

13.

Tanaka T, Narazaki M, Kishimoto T . Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2017; 10(8). PMC: 6071487. DOI: 10.1101/cshperspect.a028456. View

14.

Noguchi T, Fujimoto H, Sano H, Miyajima A, Miyachi H, Hashimoto Y . Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett. 2005; 15(24):5509-13. DOI: 10.1016/j.bmcl.2005.08.086. View

15.

Zhang H, Shi N, Diao Z, Chen Y, Zhang Y . Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. Genes Dis. 2021; 8(1):38-47. PMC: 7859422. DOI: 10.1016/j.gendis.2020.02.004. View

16.

Panda S, Jain S . New trifluoromethyl quinolone derivatives: synthesis and investigation of antimicrobial properties. Bioorg Med Chem Lett. 2013; 23(11):3225-9. DOI: 10.1016/j.bmcl.2013.03.120. View

17.

Singh P, Kaur S, Kumar V, Bedi P, Mahajan M, Sehar I . Synthesis and in vitro cytotoxic evaluation of N-alkylbromo and N-alkylphthalimido-isatins. Bioorg Med Chem Lett. 2011; 21(10):3017-20. DOI: 10.1016/j.bmcl.2011.03.043. View

18.

Pannunzio A, Coluccia M . Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature. Pharmaceuticals (Basel). 2018; 11(4). PMC: 6316056. DOI: 10.3390/ph11040101. View

19.

Panda S, Girgis A, Thomas S, Capito J, George R, Salman A . Synthesis, pharmacological profile and 2D-QSAR studies of curcumin-amino acid conjugates as potential drug candidates. Eur J Med Chem. 2020; 196:112293. DOI: 10.1016/j.ejmech.2020.112293. View

20.

Lima Leite A, Espindola J, de Oliveira Cardoso M, Bezerra de Oliveira Filho G . Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases. Curr Med Chem. 2017; 26(23):4323-4354. DOI: 10.2174/0929867324666171023163752. View